TG
EGRX

TCW Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

TCW Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-15,986
Closed -$647K – 698
2016
Q1 		$647K Sell
15,986
-18,991
-54% -$1.2M ﹤0.01% 589
2015
Q4 		$3.1M Buy
34,977
+12,668
+57% +$1M 0.02% 273
2015
Q3 		$1.65M Buy
+22,309
New +$1.86M 0.01% 399

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

TCW Group's EGRX Position: Q2 2016 in Review

TCW Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 15,986 shares — an estimated $647K sold.

TCW Group first reported a position in EGRX in Q3 2015 and held it in 3 quarters. The position peaked at $3.1M in Q4 2015. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

  • TCW Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • TCW Group sold 15,986 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $647K.
  • TCW Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
  • TCW Group's Eagle Pharmaceuticals, Inc. position peaked at $3.1M in Q4 2015.
  • 116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on TCW Group's 13F filing for Q2 2016, filed 12 Aug 2016.